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Aim To evaluate the cytotoxic action of 4-thiazolidinone de-
rivatives (ID 3288, ID 3882, and ID 3833) toward rat glioma 
C6 cells and to compare the effects of these compounds 
and doxorubicin on the balance of free radical oxidation 
(FRO) and antioxidant activity (AOA) in the serum of rats.
Methods Glioma cells were treated with ID 3882, ID 3288, 
ID 3833, and doxorubicin, and their cytotoxicity was studied 
using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide) assay and Trypan blue exclusion test, light 
and fluorescent microscopy, and flow cytometric study of 
cell cycling and apoptosis, including measuring of Annexin 
V-positive cells. The contents of superoxide radical, hydro-
gen peroxide, hydroxyl radical, malonic dialdehyde, and hy-
drogen sulfide were measured in the serum of rats. Enzy-
matic activity of superoxide dismutase (SOD), catalase (Cat), 
and glutathione peroxydase (GPO) was determined.
Results Among novel 4-thiazolidinone derivatives, ID 3288 
was most toxic toward rat glioma C6 cells, even compared 
with doxorubicin. All applied derivatives were less active 
than doxorubicin in inducing reactive oxygen species-re-
lated indicators in the serum of rats. A similar effect was ob-
served when enzymatic indicators of AOA processes were 
measured. While doxorubicin inhibited the activity of SOD, 
GPO, and Cat, the effects of 4-thiazolidinone derivatives 
were less prominent.
Conclusion Novel 4-thiazolidinone derivatives differ in their 
antineoplastic action toward rat glioma C6 cells, and ID 3288 
possesses the highest activity compared to doxorubicin. 
Measurement of indicators of FRO and AOA in the serum of 
rats treated with these compounds showed their lower gen-
eral toxicity compared with doxorubicin’s toxicity.
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Chemotherapy is one of the most effective ways of treat-
ing cancer patients. Chemotherapeutic drugs suppress 
proliferation or irreversibly impair tumor cells via a direct 
interaction with the nucleic acids or enzymes that are re-
sponsible for their synthesis or functioning (1). General-
ly, these drugs impair rapidly proliferating cells, however 
they do not possess enough selectivity regarding their 
cell targets. Thus, their application in cancer treatment is 
accompanied by frequent non-addressed actions lead-
ing to numerous negative side effects in the organism 
(1-3). Due to these effects, they demonstrate toxicity to-
ward different normal cells in tissues and organs, among 
which there are the bone marrow cells, mucous layer of 
the intestine, reproduction glands, and hair follicles. Al-
though the list of clinically used anticancer drugs is rath-
er long, a search for new drugs continues and, currently, 
many new drugs are at different phases of preclinical and 
clinical trials (4).
The anticancer potential of synthetic derivatives of het-
erocyclic 4-thiazolidinones was approved by the Devel-
opment Therapeutics Program of screening new antican-
cer compounds at the National Сancer Institute (USA) (4). 
Our previous study of anticancer activity of the 4-thiazo-
lidinones, including pyrazoline-substituted compounds, 
showed that pyrazoline-thiazolidinone-indoline conju-
gates were the most promising candidates for further pre-
clinical study, and the compounds denoted as ID 3288, ID 
3833, and ID 3882 were the most active among them (4,5). 
Their structure is shown in Figure 1, and their molar masses 
are 559.44 (ID 3288), 530.61 (ID 3882), and 609.51 g/mol (ID 
3833). The main structural feature of these compounds is 
the presence of Br atom in the isatin fragment (5th position 
of ID 3288 and ID 3833) and substitution of the phenyl sub-
stituent (ID 3288) in the 3rd position of the pyrazoline cycle 
by the naphtyl fragment (ID 3833 and ID 3882) (4,5). These 
specific fragments might have a decisive influence on the 
cytotoxic action of the compared compounds. Therefore, 
the compounds ID 3288, ID 3833, and ID 3882 were select-
ed for further in-depth in vitro and in vivo studies (4,6,7). 
They are structurally similar, belong to the patented group 
of the pyrazoline-thiazolidinone-isatins, and possess the 
antineoplastic activity toward cultured mammalian tumor 
cells. It should be stressed that they demonstrated lower 
general toxicity in vivo compared with the toxicity of doxo-
rubicin (2,3,8).
The biochemical mechanisms responsible for a lower gen-
eral toxicity of studied 4-thiazolidinones derivatives com-
pared with doxorubicin have not yet been explained. Here 
we demonstrated that the compounds ID 3288, ID 3833, ID 
3882 and doxorubicin differentially affected the balance of 
free radical oxidation (FRO) and antioxidant activity (AOA) 
in the target cells, which could be a reason of their differ-
ent toxicity.
It is known that the action of many anticancer drugs is 
accompanied by an elevated production of reactive ox-
ygen species (ROS), which are toxic for both normal and 
malignant cells (1,9,10). At the same time, malignant cells 
are characterized by the innate high level of ROS, which 
are considered to be the promoters of tumor progression 
(11,12). In order to neutralize the negative effects of ROS, 
tumor cells possess the mechanisms of antioxidant de-
fense, and, thus, a balance of pro- and antioxidants exists 
in tumor (10-12). The redox adaptation through up-regu-
lation of the anti-apoptotic and antioxidant molecules al-
lows cancer cells to promote survival and develop resis-
tance to anticancer drugs (10,12,13). The deterioration of 
such adaptation, for example by decreasing their antioxi-
dant capacity by means of specific anticancer drugs, is a 
perspective way of enhancing the effectiveness of drug 
action (1,11).
Recently, we have found that the injection of compounds 
ID 3882, ID 3288, and ID 3833 to experimental rats is ac-
companied by a decrease in biochemical indicators of the 
negative side effects, such as cardio-, hepato-, and neph-
rotoxicity, although their magnitude was lower than in the 
case of doxorubicin (2,3,8).
FIGuRe 1. Structure of the studied 4-thiazolidinone derivatives 
– compounds ID 3882, ID 3288 and ID 3833.
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The aim of present study was to determine the toxicity of 
novel 4-thiazolidinone derivatives (compounds ID 3288, 
ID 3882, and ID 3833) and doxorubicin (positive control) 
toward rat glioma C6 cells. Besides, the role of ROS mea-
sured in the serum of rats treated with the above men-
tioned compounds and doxorubicin was evaluated, and 
the enzymatic activity of superoxide dismutase (SOD), 
catalase (Cat), and glutathione peroxydase (GPO) was de-
termined.
MateRIaLS aND MethODS
Drugs. The heterocyclic 4-thiazolidinones derivatives (com-
pounds ID 3288, ID 3882 and ID 3833) were synthesized 
at the Department of Pharmaceutical, Organic and Bioor-
ganic Chemistry of Danylo Halytsky Lviv National Medi-
cal University in 2012, as described (4,5). Before use, they 
were dissolved in the dimethyl sulfoxide (DMSO, Arterium, 
Lviv, Ukraine), and then additionally dissolved in distilled 
water before use. The final concentration of the DMSO in 
the medium of cultured cells was below 0.1%. Doxorubicin 
was purchased from local representative of Pfizer Inc. (New 
York, USA).
Cell culture. Rat glioma cells of C6 line used in the experi-
ments were obtained from the Collection of the Institute 
of Molecular Biology and Genetics, National Academy of 
Science of Ukraine (Kyiv, Ukraine). Cells were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM, Sigma, St. 
Louis, USA) supplemented with 10% fetal bovine serum 
(Sigma). Cells were grown in CO2-incubator at 37°C, 5% CO2 
and 95% humidity. The reseeding of cells was performed at 
a ratio of 1:5 once in 2-3 days.
Determination of cytotoxic action of studied substances. 
Cells were plated in 96- or 24-well plates (Greiner Bio-
One GmbH, Kremsmünster, Austria). The substances un-
der study were added at various concentrations imme-
diately after cell seeding without the adaptation period. 
Counting of the cell number was carried out at regular 
intervals in the hemocytometer (counting chamber) us-
ing Trypan Blue dye (DV-T10282, Invitrogen, Life Technol-
ogies Corporation, Waltham, MA, USA) at 0.01% final con-
centration, 2 min after its addition to cell suspension. The 
dead cells uptake this dye due to their plasma membrane 
damage.
Cell viability and proliferation assay. MTT assay was used 
for assessing cell metabolic activity. NAD(P)H-dependent 
cellular oxidoreductases are reducing 3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) to its in-
soluble formazan dissolved in the DMSO and measured by 
the colorimetric analysis as a purple color. After drug treat-
ment, the MTT assay of viable cells was conducted in accor-
dance with the manufacturer’s recommendations (Sigma). 
Product of the reaction was quantitatively determined by 
an Absorbance Reader BioTek ELx800 (BioTek Instruments, 
Inc., Winooski, VT, USA) at 620 nm wavelength.
Light and fluorescent microscopy. The living, apoptotic 
and necrotic cells were viewed under the inverted light 
microscope Biolam (LOMO, St Petersburg, Russian Federa-
tion). Images were processed with a fluorescent Zeiss mi-
croscope (Carl Zeiss, Jena, Germany) using AxioImager A1 
camera, at ~ 400 times magnification in the relevant sec-
tions of the excitation and emission.
Rat glioma C6 cells were seeded on glass microscopic 
slides in the 24-well plates (Greiner bio-one). The substanc-
es were added in different concentrations in 24 hours af-
ter cell seeding. Material of cell nucleus was stained with 
the DNA-specific fluorescent dye Hoechst 33342 (Sigma). 
The cells were also stained by the poly-specific dye Acri-
dine orange (AO, Sigma) (14). These fluorochromes were 
added to cultured cells at following final concentrations: 
AO – 0.3-1.0 µg/mL, Hoechst 33342-0.2-0.5 µg/mL, and the 
cells were incubated for 20-30 min.
Flow cytometry. For cell cycling and apoptosis study, C6 
glioma cells treated with various agents were washed 
with phosphate buffered saline (PBS, pH 7.4), pelleted by 
centrifugation at 1000 rpm for 5 min at 4°C, and re-sus-
pended in cold PBS (2 mln cells per 1 mL of the PBS). Then, 
cells were fixed via dropwise adding of cooled (-20°C) ab-
solute ethanol (total volume 4 mL) with gentle mixing. 
The obtained fixed samples were kept at -20°C until use 
(no longer than 1 week). For conducting FACS analysis, 
cell samples were centrifuged at 1000 rpm for 5 min at 
4°C, the supernatant was discarded, and the cell pellet 
was re-suspended in 1 mL of PBS. 100 uL of DNAase-
free RNAase (Sigma) were added to that suspension, and 
samples were incubated at 37°C for 30 min. Then, each 
sample was supplemented with 100 uL of the Propidium 
iodide (Sigma, 1 mg/mL) and incubated at room temper-
ature for 10 min. The samples were transferred to plastic 
Falcon tubes, and cell suspension was monitored at the 
FACScalibur flow cytometer (BD Biosciences, Mountain 
View, CA, USA) and Summit v3.1 software (Cytomation, 
Inc., Fort Collins, CO, USA) was used for measuring the pa-
rameters of cell cycle and apoptosis.
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Measurement of the Annexin V-positive (apoptotic) cells 
was performed by FACS analysis. Glioma C6 cells were 
treated as indicated in the figures. At the end of the experi-
ment, the cells were detached from the bottom of the dish 
with trypsin-EDTA solution, washed twice with the PBS, 
and stained with Annexin V-FITC using apoptosis detec-
tion kit (BD Pharmingen, San Diego, CA, USA), according to 
the manufacturer’s instructions. In particular, washed cells 
were incubated for 15 min in the Annexin V binding buf-
fer containing 1/50 volume of FITC-conjugated Annexin 
V solution. Then, the samples were diluted twice with an 
appropriate volume of the Annexin V binding buffer and 
immediately measured on FL1/FL2 (FITC-PI) channel of the 
flow cytometer device (Becton Dickinson, Franklin Lakes, 
NJ, USA). The Annexin V-single positive cells were classified 
as apoptotic.
Animal study. All experiments with experimental rats were 
conducted under the control of the BioEthics Commission 
at Danylo Halytsky Lviv National Medical University (Proto-
col N2 dated by 16.02.2015) (15,16). Mature white labora-
tory rats with body mass of 200-220 g were kept on a stan-
dard fodder in animal facility with adequate lighting and 
temperature conditions.
Drugs were administered to animals every day in the 
morning before the first meal. Rats had an access to wa-
ter all the time (24 h). Such a mode of administration of 
drugs is common in preclinical study of medicines (17). 
The experiment lasted for 10 days for animals that received 
doxorubicin and for 20 days for animals that received the 
synthetic compounds with anticancer potential. Doxoru-
bicin was injected starting from the dose of 5.5 mg/kg, the 
compounds ID 3882 and ID 3833 – starting from the dose 
of 10.7 mg/kg, and the compound ID 3288 – starting from 
the dose of 24.3 mg/kg. The dose was gradually elevated 
by 1.5 times per 4 days in order to achieve a cumulative ef-
fect. The starting dose was equaled by 10% of maximum 
injected dose in experiments for LC50 determination (8). Ex-
perimental groups used in the study: 1 – control (intact an-
imals, n = 20); 2 – doxorubicin injection (n = 20); 3 – ID 3288 
injection (n = 20); 4 – ID 3882 injection (n = 20); 5 – ID 3833 
injection (n = 20). The rats were euthanized on the 10th or 
20th day by decapitation under thiopental anesthesia (17). 
Blood was used to obtain serum.
Measurement of ROS and MDA in blood serum of treated 
rats. The content of generated superoxide radical was mea-
sured by the oxidation of the cytochrome c (Sigma) defined 
as an optical density at 550 nm (18). The content of hydroxyl 
radical was measured in the incubation medium with 2-de-
oxy-D-ribose (Sigma) defined as an elevation of the malon-
ic dialdehyde (MDA) by absorption at 532 nm (19). Means 
of both indicators were presented as the arbitrary units of 
changed extinction per 1 min in 1 mL of blood serum. The 
content of H2O2 was measured, as previously described (20). 
For measuring the malonic dialdehyde, 0.5 mL of 1% solu-
tion of the tiobarbituric acid in 50 mM NaOH and 0.5 mL of 
2.8% solution of trichloracetic acid were added to the ali-
quots of blood serum. The mixture was kept for 20 min in 
boiling water bath cooled to room temperature, and optical 
density was determined at 532 nm (18).
Measurement of the enzymatic activity of the antioxi-
dant system was conducted as follows. The activity of 
gluthatione peroxidase (GPO, EC 1.11.1.9) was measured 
spectrophotometrically at λ = 262 nm, as a quantity of the 
reduced gluthatione. It was expressed in the micromoles 
of reduced gluthatione per 1 min in 1 mL. Catalase activity 
(CAT, EC 1.11.1.6) was determined by measuring the de-
crease in the hydrogen peroxide concentration at 410 nm. 
The assay medium consisted of 1 mL Tris-HCl buffer solu-
tion (0.05 mmol, pH 7.8), 0.1 mL of blood serum sample, 
and 2 mL of 0.03% H2O2. The reaction was stopped after 10 
min incubation by adding 1 mL of 4% ammonium molyb-
date. Spectrophotometric measurement was conducted 
at 410 nm, and the activity of blood serum CAT was ex-
pressed as the micromoles of H2O2/min per mg of pro-
tein. The activity of superoxide dismutase (SOD, EC1.15.1.1) 
was determined in the reaction of reduction of the nitro-
tetrazolium blue to the nitroformazan. The assay medium 
contained 0.1 mL of blood serum (1:10 dilution), 0.9 mL of 
distilled water, 0.5 mL of absolute ethanol, 0.25 mL of chlo-
roform, and 0.3 g KH2PO4. The mixture was shaken vigor-
ously, centrifugated (5000 rpm, 30 min), and 0.1 mL of NA-
DPH and 0.05 mL of the incubation solution (37 mg EDTA, 
330 mg p-iodonitrotetrazolium violet, 55 mg phenazine 
methosulfate were added to a supernatant and incubat-
ed for 10 min at 20°C. The absorbance was immediately 
read at 540 nm in a Stat fax. SOD activity was expressed in 
μmol/min per mg of protein. Н2S content was determined 
in the reaction with N,N-dimethyl-para-phenyldiamine in 
the presence of FeCl3 (21).
Data analysis and statistics. All experiments were repeated 
three times with three parallels in each variant. The analysis 
of variance (ANOVA) was used as a statistical test for com-
parison of groups. All data are presented as a mean ± SD. 
Results were analyzed using GraphPad Prism software. Sta-
tistical analyses were performed using t test or two-way 
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analysis of variance (ANOVA). To examine differences be-
tween drug treatment responses, Bonferroni post-hoc 
tests were conducted. P values below 0.05 were consid-
ered as statistically significant.
ReSuLtS
Cell viability assay and trypan blue exclusion testing of 
cytotoxic action of 4-thiazolidinone derivatives
The MTT assay was applied for measuring the cytotoxic ef-
fect of the studied compounds ID 3288, ID 3882, ID 3833 
and doxorubicin on rat glioma C6 cells. The compound ID 
3288 was the most effective, and its activity was even high-
er (48 h treatment) than the activity of doxorubicin (Figure 
2). The compound ID 3882 demonstrated some cytotoxic-
ity only at a high dose (1 µg/mL) and at longer (48 h) treat-
ment, while the cytotoxicity value of ID 3833 was between 
the values for ID 3288 and ID 3882.
In general, the pattern of the cytotoxic action of the stud-
ied compounds and doxorubicin obtained by Trypan blue 
exclusion test was similar to the pattern obtained by the 
MTT assay. Particularly, the compounds ID 3288 and ID 
3833 demonstrated similar cytotoxicity as doxorubicin at 
both time points of measurement – 24 and 48 h (Figure 
2). It should be noted that the compound ID 3882 did not 
change significantly the number of Trypan-blue positive 
(dead) cells even when used at a high dose (1 µg/mL).
These results correspond with the values of 50% inhibition 
concentration (IC50) determined by the MTT assay and 50% 
lethal concentration (LC50) determined by the Trypan blue 
exclusion test in rat glioma C6 cells treated for 24 and 48 h 
with the compounds ID 3288, ID 3833, ID 3882, and doxo-
rubicin (positive control). The studied compounds showed 
a time dependent action, and the compound ID 3288 was 
the most cytotoxic, while the compound ID 3882 was non-
toxic (Table 1).
FIGuRe 2. Dynamics in the number of alive rat glioma C6 cells under treatment for 24 h and 48 h with 4-thiazolidinone derivatives 
– compounds ID 3288, ID 3833, and ID 3882 compared with the action of doxorubicin (positive control). Negative control – 100% 
(untreated cells cultured for 24 h and 48 h, respectively). (A) – Mtt assay 24h; (B) – Mtt assay 48 h; (C) – trypan blue assay 24 h; (D) – 
trypan blue assay 48h. * – P ≤ 0.05; ** – P ≤ 0.01, *** – P ≤ 0.001 (difference compared with the negative control).
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Cytomorphological characteristics of glioma C6 cells 
treated with 4-thiazolidinone derivatives
The microscopic study of the cytomorphological charac-
teristics of the treated glioma C6 cells demonstrated that 
doxorubicin and compound ID 3288 used at 1 µg/mL dose 
caused the most drastic changes in cell intactness, name-
ly a decrease in cell density in vitro, a decrease in cell size, 
probably due to apoptotic condensation of cell body, and 
appearance of cell debris (Figure 3). Besides, doxorubicin 
induced a development of red color staining of cells in the 
presence of the Acridine orange dye (Figure 3). Other com-
pounds (ID 3288 and ID 3833) impaired cell morphology to 
a lesser extent than the ID 3288.
FaCS analysis of changes in cell cycling induced by 
4-thiazolidinone derivatives
FACS analysis of cell cycling and apoptosis is a sensitive 
test for evaluating the effect of various agents on cell func-
tioning and viability, and we used this approach to mea-
sure the cytotoxic action of the studied 4-thiazolidinone 
derivatives. Its results are presented in Table 2. There was 
a clear time and dose dependence of cytotoxicity (num-
ber of pre-G1 apoptotic cells) of these agents (excluding 
the compound ID 3882) targeting rat glioma C6 cells. The 
ID 3882 did not disturb cell cycling considerably, and this 
is in agreement with the results of MTT assay, Trypan blue 
exclusion test, and cytomorphological study.
FaCS analysis of apoptosis induced by 4-thiazolidinone 
derivatives
The results presented above on the amount of the pre-G1 
phase (Table 2) correspond with the results of measuring 
the Annexin V-single positive cells classified as apoptotic 
ones (Figure 4).
Flow cytometry study conducted after double staining 
(Annexin V+/Propidium Iodide+) of rat glioma C6 cells 
treated for 24 h with the compounds ID 3288, ID 3833, and 
doxorubicin (positive control) clearly demonstrated that 
the compound ID 3288 dose-dependently (0.5 and 1.0 µg/
mL) induced apoptosis in these cells (Figure 4). The num-
ber of pre-G1 cells treated with ID 3288 (Table 2) was com-
taBLe 1. Values of IC50 determined by the Mtt assay and of 
LC50 determined by the trypan blue exclusion test in rat 
glioma C6 cells treated for 24 and 48 h with the compounds ID 
3288, ID 3833, ID 3882, and doxorubicin (positive control).
Mtt (IC50, μg/mL) trypan blue (LC50, μg/mL)
Drugs 24 h 48 h 24 h 48 h
Dox 0.71 0.51 0.84 0.07
3288 0.43 0.10 0.13 0.07
3833 0.84 0.23 0.89 0.08
3882 non-toxic 0.98 non-toxic non-toxic
FIGuRe 3. Rat glioma C6 cells after 24 h treatment with the 
studied compounds (A), (B) – control; (C), (D) – ID 3288; (E), (F) 
– ID 3833, (G), (H) – ID 3882) and doxorubicin (positive control, 
(I), (J), all used in 1 µg/mL dose. Left – fluorescent image of 
treated cells (blue color – staining with fluorescent DNa-spe-
cific dye hoechst-33342, red and green color – staining with 
poly-specific fluorescent dye acridine orange). Right – DIC 
image of treated cells.
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parable with the sum of numbers of apoptotic (AnV+/PI+) 
and necrotic (AnV-/PI+) cells (Figure 4). An increased num-
ber of AnV+/PI+ cells under treatment with ID 3288 was 
bigger than in the case of doxorubicin treatment, and the 
effect of ID 3833 was weaker than the effect of doxorubi-
cin, both used at 1.0 µg/mL concentration. DMSO (used for 
dissolving the 4-thiazolidinone derivatives under study) in 
both doses (0.5 and 1.0 µg/mL) was relatively non-toxic for 
glioma cells (Table 2), and it did not significantly affect cell 
cycling or induce apoptosis (Figure 4). These results sug-
gest that the compound ID 3288 can potentially be used 
for treatment of mammalian gliomas.
Measurement of biochemical mediators of the action of 
4-thiazolidinone derivatives in the serum of rats
We also measured the level of ROS in the serum of rats. 
The level of superoxide radical in serum was not changed 
by doxorubicin, while it was decreased by 46% and 24% 
after the injection of the compounds ID 3288 and ID 3882, 
respectively (Figure 5). The compound ID 3833 did not 
change the level of superoxide radical significantly.
An injection of the doxorubicin led to a significant (2.2 
times) increase in the content of the hydroxyl radical in 
the serum of treated rats, while the injection of all studied 
4-thiazolidinone derivatives (ID 3288, ID 3882, ID 3833) de-
creased its content by 2-3 times (Figure 5).
In general, the ability of the compounds ID 3288, ID 3882, 
ID 3833 and doxorubicin to induce the production of hy-
drogen peroxide is similar to their ability to induce super-
oxide and hydroxyl radical (Figure 6). While doxorubicin 
and the ID 3833 increased approximately twice the con-
tent of the hydrogen peroxide in the serum of treated rats, 
the ID 3288 did not change it significantly, and ID 3882 de-
creased such content by 30%.
Here, we found that doxorubicin increased the content of 
H2S by 75%, while the compounds ID 3288 and ID 3882 de-
taBLe 2. Results of typical FaCS analysis of the number of cell cycle phases – pre-G1 (apoptotic), G1, S, and G2/M – in rat glioma C6 
cells treated with compounds ID 3288, ID 3882, ID 3833 and doxorubicin (positive control) used in 0.1 and 1.0 µg/mL doses for 24 
and 48 h
Doxorubicin 3288 3833 3882
24 h Control 0.1 µg/mL 1.0 µg/mL 0.1 µg/mL 1.0 µg/mL 0.1 µg/mL 1.0 µg/mL 0.1 µg/mL 1.0 µg/mL
Pre-G1  3.83  4.55 15.89  3.93 53.75  3.79 26.51  3.12  4.39
G1 63.4 58.96 56.37 62.04 31.16 60.62 50.49 60.81 64.98
S 11.54  5.07 13.51 11.5  4.56 12.09  6.96 12.06  8.41
G2 20.13 30.67 15.16 20.95 10.86 21.46 16.13 21.53 20.44
Doxorubicin 3288 3833 3882
48 h control DMSO 0.1 µg/mL 0.1 µg/mL 0.1 µg/mL 0.1 µg/mL
Pre-G1  3.89  0.81 18.98 87.84  5.41  7.71
G1 62.33 72.92 52.39 10.12 59.34 66.01
S 13.97  7.99  6.13  0.84 11.14  9.39
G2 19.96 16.71 22.41  1.28 20.51 16.85
FIGuRe 4. effect of compounds ID 3288, ID 3833 and doxorubicin in 0.5 and 1.0 µg/mL concentrations (24 h) on induction of apopto-
sis in rat glioma C6 cells. Results of flow cytometry of cells after annexin V (anV) and Propidium iodide (PI) double staining.
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creased such content by 57% and 35%, respectively, and the 
compound ID 3833 did not affect it significantly (Figure 6).
While doxorubicin and the compound ID 3833 increased 
twice the content of the malonic dialdehyde in the serum 
of treated rats, the ID 3288 and ID 3882 did not affect that 
content (Figure 7).
Measurement of the activity of enzymes of the 
antioxidant system in the serum of rats
The activity of enzymes of the antioxidant system – SOD, 
Cat and GPO – was measured in the serum of treated rats. 
The activity of the GPO was decreased under the action 
of all studied anticancer compounds, while the activity of 
SOD was decreased only by doxorubicin and the ID 3833 
(Figure 8,9). In general, these data correspond with the re-
sults obtained when the ROS were measured in the same 
variants of the experiment. The dynamics of the Cat activity 
under the action of doxorubicin (35% decrease) was similar 
to the dynamics detected for the SOD and GPO activities. 
However, the effect of the ID 3288 and ID 3833 was dif-
ferent since they increased the activity of Cat by 40% and 
20%, respectively (Figure 8,10).
Thus, the action of the compounds ID 3288, ID 3833 and ID 
3882 was accompanied by a lower increase in ROS content 
and a lower decrease in the activity of enzymes of the antioxi-
dant system, compared with such actions of the doxorubicin.
DISCuSSION
We used four different approaches for evaluating toxic ac-
tion of the 4-thiazolidinone derivatives (compounds ID 
3882, ID 3833, ID 3288) and doxorubicin on rat glioma C6 
cells: 1) MTT (cell viability and proliferation) assay; 2) Trypan 
FIGuRe 5. Concentration of superoxide radical and hydroxyl 
radical in the serum of rats injected with doxorubicin and the 
compounds ID 3288, ID 3882, and ID 3833. * – P ≤ 0.05; ** – 
P ≤ 0.01, *** – P ≤ 0.001 (difference compared with the control).
FIGuRe 6. Concentration of hydrogen peroxide and hydrogen 
sulfide in the serum of rats injected with doxorubicin and the 
compounds ID 3288, ID 3882 and ID 3833. * – P ≤ 0.05; ** – 
P ≤ 0.01, *** – P ≤ 0.001 (difference compared with the control).
FIGuRe 7. Concentration of the malonic dialdehyde in the 
serum of rats injected with doxorubicin and the compounds 
ID 3288, ID 3882 and ID 3833. *** – P ≤ 0.001 (difference com-
pared with the control).
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blue exclusion test for cytotoxicity; 3) cytomorphological 
(microscopic) study of cell intactness; 4) study of cell cy-
cling and apoptosis (flow cytometry). A specific ranking 
of cytotoxicity of the applied drugs was formulated taking 
into account the results of these tests.
Evaluation of the vitality and survival (MTT assay) of treat-
ed cells showed the following ranking of increasing toxic-
ity of 4-thiazolidinone derivatives toward the glioma cells: 
ID 3882<ID 3833<ID 3288 ≈ doxorubicin. This ranking was 
found to be true when the MTT assay was applied for mon-
itoring the results of 24 h treatment with median (0.1-0.25 
µg/mL) doses of the compared agents, while at 48 h treat-
ment with the same doses, it was somewhat changed: ID 
3882<ID 3833<doxorubicin<ID 3288. There was no big 
difference between the action of the studied drugs used 
in low (0.05 µg/mL) and high (1.0 µg/mL) doses, with an 
exception of the compound ID 3882 which demonstrated 
very low toxicity toward the glioma cells.
The ranking of the toxic action (Trypan blue exclusion 
test) of 4-thiazolidinone derivatives and doxorubicin on 
rat glioma C6 cells was the following: ID 3882<ID 3833 ≈ ID 
3288 ≈ doxorubicin at both 24 and 48 h duration of cell 
treatment. Thus, it was similar to that observed when 
the MTT assay for cell vitality and survival was used (see 
above).
4-thiazolidinone derivatives used in this study were also 
tested for their toxicity toward other mammalian tumor 
FIGuRe 8. Superoxide dismutase activity in the serum of rats 
injected with doxorubicin (Dox) and the compounds ID 3288, 
ID 3882, and ID 3833. * – P ≤ 0.05; ** – P ≤ 0.01, *** – P ≤ 0.001 
(difference compared with the control).
FIGuRe 9. Glutathione peroxidase activity in the serum of rats 
injected with doxorubicin (Dox) and the compounds ID 3288, 
ID 3882, and ID 3833. * – P ≤ 0.05; ** – P ≤ 0.01, *** – P ≤ 0.001 
(difference compared with the control).
FIGuRe 10. Catalase activity in the serum of rats injected with 
doxorubicin (Dox) and the compounds ID 3288, ID 3882, and 
ID 3833. * – P ≤ 0.05; ** – P ≤ 0.01, *** – P ≤ 0.001 (difference 
compared with the control).
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cells, such as murine leukemia L1210 cells, human T leuke-
mia Jurkat cell line (6), and human melanoma WM793 cells 
(our paper under preparation). The compound ID 3833 
was found to be the most cytotoxic (6). As shown in this 
study, the ID 3288 was the most cytotoxic for rat glioma 
cells, compared with the ID 3833 and 3882. Thus, one can 
suggest an existence of specific action of the ID 3288 on 
rat glioma cells. It was also shown that the ID 3833 was as 
toxic as doxorubicin for human embryonal kidney HEK-293 
cells, while the ID 3288 and 3882 were not toxic for these 
cells (our unpublished data).
It was rather complicated to quantify the cytotoxicity lev-
els by using the cytomorphological (microscopic) studies. 
However, the results of these studies, as well as that of pre-
vious tests, showed the highest toxicity of the compound 
ID 3288 and the lowest toxicity of the ID 3882 for rat glioma 
C6 cells.
The same conclusion can be done based on the results of 
FACS analysis on the ratio of the apoptotic (pre-G1) glio-
ma C6 cells appearing under their treatment with studied 
agents. While at 24-h cell treatment with this compound 
in 1.0 µg/mL dose, the pre-G1 peak on the cytofluoro-
gram reached 53.75%, a longer duration (48 h) treatment 
with 10 times lower dose (0.1 µg/mL) of the ID 3288 led 
to massive (87.84%) death of the glioma cells, suggesting 
their secondary necrosis. This suggestion corresponds with 
the results of Trypan blue exclusion test measuring the ne-
crotic cells. Thus, the glioma cells treated with the com-
pound ID 3288 really die and are not simply metabolically 
suppressed. The results of the cytomorphological study of 
such cells also demonstrated that they had a decreased 
size and round form, and, moreover, they frequently pos-
sessed a damaged morphology (surface). Besides, signs of 
lysosome activation were observed in their cytosol regions 
as red staining by the Acridine orange (14). The action of 
the ID 3833 and ID 3288 was less destructive for the glioma 
cells. As a rule, changes in cell vitality and survival, as well 
as cell damage, are secondary to the deregulation of cell 
cycling and development of the apoptotic characteristics 
in cells (22).
Taking into account the results of our comparative studies 
of the cytotoxic action of three different 4-thiazolidinone 
derivatives (ID 3288, ID 3833 and 3882) and doxorubicin 
(positive control), one can ask a question – why the ID 3288 
is the most damaging agent for rat glioma cells and the ID 
3833 is the next in this ranking, while the ID 3882 is rela-
tively non-toxic agent. It should be noted that in the struc-
ture of the ID 3288 and ID 3833, opposite to the ID 3882, 
Br atom is present in 5th position of the isatin fragment 
of their molecules, and the phenyl substituent is present 
in the 3rd position of the pyrazoline cycle of the ID 3288. 
However, additional investigation should be performed 
for more detailed analysis of structure-functional interrela-
tions of the 4-thiazolidinone derivatives.
We found in the in vivo experiments that the compounds 
ID 3288 and ID 3833 induced the effects typical for the ac-
tion of the doxorubicin. These are an increase in the level of 
the ROS and a decrease in the activity of the enzymes of the 
antioxidant system. It is evident that a proper modulation 
of the level of induced ROS and of the antioxidant activity 
might be a useful strategy to decrease the negative con-
sequences of general toxicity accompanying the action of 
most anticancer drugs (9,12). This could be achieved by the 
combination of chemotherapy and antioxidants (10,13), al-
though the application of such approach in cancer treat-
ment has been criticized (23,24).
The main mechanism of the antioxidant defense is not 
based on a direct inhibition of reactions of free radical oxi-
dation by various antioxidants. It mostly depends on a pre-
cise regulation of interrelations between pro- and antiox-
idant systems and a support of the antioxidant status in 
the organism via a flexible regulation of the metabolic pro-
cesses (12,13,24-26). The negative side effects of anticancer 
drugs are related to a disturbance in the system of free rad-
ical processes, whose excess activation cannot be neutral-
ized by a system of the antioxidant defense (9,11,25,26).
Our experiments show that doxorubicin induces an ele-
vation of the superoxide and hydroxyl radicals, which are 
highly toxic and whose action is considered to be one of 
the main reasons of negative side effects of this antibiot-
ic in the organism (9-12). Significantly lower contents of 
these radicals in the serum of rats treated with the com-
pounds ID 3288 and ID 3882, compared with such con-
tents found in the serum of rats treated with doxorubicin 
and compound ID 3833, are in agreement with our pre-
vious results of measuring the biochemical indicators (ac-
tivity of creatine kinase, lactate dehydrogenase, aspartate 
aminotransferase, and alanine aminotransferase) of the 
cardiotoxicity in rats (2,3).
H
2O2 was also strongly induced by doxorubicin and com-
pound 3833, and not changed by the compounds 3288 
and 3882. Besides, the level of malonic dialdehyde was 
increased by doxorubicin and the compound 3833, but 
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not by the compounds 3288 and 3882. The malonic dial-
dehyde is considered to be an integrated indicator of ROS 
production under the action of various stressing agents, 
including anticancer drugs (18).
General pattern of changes of the H2S in the serum of rats 
treated with the compounds ID 3288, ID 3882, ID 3833, and 
doxorubicin was similar to the patterns of changes of spe-
cific ROS and malonic dialdehyde. That is an elevation of 
the content of H2S under the action of doxorubicin and a 
decrease of such content by the compounds ID 3288 and 
ID 3882. However, while the ID 3833 increased the level of 
such ROS as H2O2, superoxide radical and the malonic dial-
dehyde, this compound did not influence significantly the 
level of H2S. After first description of H2S role as a regulator 
of a variety of such processes, it has been intensively stud-
ied (21). H2S enhanced the apoptotic death of the mam-
malian cells in vitro using the mitochondrial pathway for 
the activation of caspase 3 and specific MAP-kinases (21). 
The pro-apoptotic action of H2S in high millimolar doses 
is accompanied by the generation of ROS and a decrease 
in the gluthatione concentration (21). Thus, the action of 
doxorubicin and the ID 3833 on H2S level correlates with a 
potential proapoptotic effect of this mediator.
The determined changes in the enzymatic system of the 
antioxidant defense in rat glioma C6 cells treated with 
4-thiazolidinone derivatives were the following: activity of 
SOD was decreased under the action of the doxorubicin 
and the compound ID 3833, but not by other compounds 
– ID 3288 and ID 3882, and the GPO activity was reduced at 
the action of all used compounds and doxorubicin. While 
only doxorubicin caused a reduction of the Cat activity, 
and the 4-tiazolidinone derivatives did not affect it.
Most metabolites and signaling mediators that appear in 
tissues and organs can also be found in the blood stream. 
Since the oxidants measured in our study are generated by 
cells, an increase in their content is also expected in blood. 
At present, we do not have direct experimental data on the 
penetration of the blood brain barrier by the compounds 
under study. Recently, it has been shown that similar het-
erocyclic compounds (1,3,4-Thiadiazolines) crossed the 
blood-brain barrier (BBB) and they were considered as an-
ticancer drugs in the preclinical xenograft models (27).
Thus, we demonstrated that novel 4-thiazolidinone deriva-
tives – the ID 3288, ID 3833 and ID 3882 – differ significant-
ly in their cytotoxic action in vitro on rat glioma C6 cells. 
The ID 3288 possessed the highest cytotoxicity that was 
comparable with such action of the doxorubicin, while the 
ID 3882 was relatively non-toxic for these cells. In vivo ac-
tion of these compounds and doxorubicin (positive con-
trol) on the level of ROS (potential mediators of toxic ef-
fects) in the blood of rats revealed the most prominent 
elevation of their level at the doxorubicin action, while the 
ID 3288 and ID 3882 were not increasing ROS level and the 
ID 3833 was in between the effects of the doxorubicin and 
these two 4-thiazolidinone derivatives. The last agents also 
decreased the activity of enzymes of the antioxidant sys-
tem (SOD, GPO, and Cat) to much lower extent, compared 
with the action of doxorubicin.
These data could be of interest for considering a com-
bined application of 4-thiazolidinone derivatives and anti-
oxidants for treatment of tumor-bearing animals, although 
presently we can nominate these derivatives only as puta-
tive anticancer drugs. The next steps in our studies will be 
focused at immobilization of the most effective 4-thiazoli-
dinone derivatives (probably, the ID 3288) on the bio-func-
tionalized nanoparticles in order to enhance drug delivery 
and antineoplastic action, as well as to improve their capa-
bility to circumvent blood-brain barrier in tumor-bearing 
animals (28).
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